Barbara Mooij
Lawyer
Barbara is a lawyer and UPC representative at Brinkhof, with vast litigation experience in Dutch and European patent law. Her expertise focuses on pharmaceutical inventions, medical devices and biotech. She also handles cases on SPCs, procedural issues, evidentiary measures and regulatory issues, such as marketing authorisations and data- and market exclusivity.
One of the ‘Key Lawyers’ in patent law
Barbara has valuable practical experience through her involvement in complex patent proceedings at both the District Court and the Court of Appeal in The Hague. Her contributions in the field have earned her recognition as one of Brinkhof’s ‘Key Lawyers’ in patent law by The Legal 500.
Experience & ancillary activities
Barbara regularly contributes to books, articles and blogs on patent law, and is a university lecturer in Patent Law at Leiden University. She is an active member of AIPPI, ChIPs and Young EPLAW. Before starting her Law studies, Barbara graduated cum laude with a BSc in Cosmetic Science, focusing on chemistry and product development. She then worked for almost two years in Unilever’s R&D department, where she helped develop and launch new products. In 2019, she obtained her Master’s in Information Law from the University of Amsterdam. Barbara was admitted to the Dutch bar in February 2020.
Some of the cases Barbara Mooij has handled:
- Represented Accord in various pharmaceutical cases, including about cinacalcet and enzalutamide.
- Acted for Gedeon Richter with regard to their adalimumab patent.
- Assisted Samsung Bioepis in an international biosimilar dispute against Regeneron.
- Represented Sandoz in various patent proceedings, such as about rivaroxaban, and proceedings on regulatory protection, such as about DMF.
